Exact Sciences Corporation ($EXAS) shares fell by approximately 30% following the release of its Q3 2024 earnings report, which revealed a GAAP loss of $0.21 per share, slightly missing the analyst consensus estimate of a loss of $0.20. The company's revenue for the quarter was reported at $708.65 million, also falling short of expectations, which were set at $717.66 million. Despite the disappointing results, some analysts anticipate that growth will accelerate in 2025, with one suggesting that they are a buyer on dips. The negative market reaction also impacted other companies in the sector, with Guardant Health ($GH) seeing a contrasting rise of approximately 25% following its earnings report.